WuXi Biologics (Cayman) Inc. (WXXWY)
OTCMKTS · Delayed Price · Currency is USD
9.99
0.00 (-0.04%)
Sep 17, 2025, 3:52 PM EDT
WuXi Biologics Employees
WuXi Biologics had 12,575 employees as of December 31, 2024. The number of employees decreased by 165 or -1.30% compared to the previous year.
Employees
12,575
Change (1Y)
-165
Growth (1Y)
-1.30%
Revenue / Employee
$223,025
Profits / Employee
$46,667
Market Cap
20.50B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 12,575 | -165 | -1.30% |
Dec 31, 2023 | 12,740 | 367 | 2.97% |
Dec 31, 2022 | 12,373 | 2,509 | 25.44% |
Dec 31, 2021 | 9,864 | 3,218 | 48.42% |
Dec 31, 2020 | 6,646 | 980 | 17.30% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Tian'an Technology Group | 8 |
Elite Pharmaceuticals | 68 |
Glass House Brands | 374 |
Northwest Biotherapeutics | 25 |
CytoDyn | 13 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
WuXi Biologics News
- 6 days ago - WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards - PRNewsWire
- 9 days ago - WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry - PRNewsWire
- 21 days ago - WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi - PRNewsWire
- 4 weeks ago - WuXi Biologics Reports Solid 2025 Interim Results - PRNewsWire
- 5 weeks ago - WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale - PRNewsWire
- 5 weeks ago - WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules - PRNewsWire
- 6 weeks ago - WuXi Biologics Named to A List for CDP Supplier Engagement Assessment - PRNewsWire
- 6 weeks ago - WuXi Biologics' Profit Guidance Signals Rebound In China's Drug Sector - Benzinga